{"schema_version":"secwatch.filing_event.v1","accession":"0001477932-24-005745","form_type":"8-K","ticker":"VNRX","cik":"0000093314","company_name":"VOLITIONRX LTD","filed_at":"2024-09-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:16.426742+00:00","generated_at":"2026-05-31T04:50:21.155317+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"confidence":"low","headline":"VolitionRx markets oncology portfolio for out-licensing via PharmaVentures","bullets":["Company engaged PharmaVentures as licensing adviser; document made available to third parties starting September 16, 2024.","Document provides brief introduction to certain components of the oncology portfolio; no specific assets or terms disclosed.","No revenue, deal value, or counterparty announced; no financial impact provided."],"urls":{"canonical":"https://secwatch.observer/filing/0001477932-24-005745","json":"https://secwatch.observer/filing/0001477932-24-005745.json","markdown":"https://secwatch.observer/filing/0001477932-24-005745.md","text":"https://secwatch.observer/filing/0001477932-24-005745.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/93314/000147793224005745/0001477932-24-005745-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/93314/000147793224005745/vnrx_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T04:50:21.155317+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}